Screening for cognitive impairment, Alzheimer’s disease and other dementias: Opinions of European caregivers, payors, physicians and the general public

被引:0
|
作者
John Bond
N. Graham
A. Padovani
J. Mackell
S. Knox
J. Atkinson
机构
[1] Newcastle University,Institute of Health and Society and Institute for Ageing and Health
[2] Alzheimer’s Disease International,Department of Medical and Surgical Sciences
[3] Università degli Studi di Brescia,undefined
[4] Pfizer Inc,undefined
[5] Eisai Europe Ltd.,undefined
[6] Pfizer Ltd,undefined
[7] Newcastle University,undefined
关键词
Alzheimer’s disease; screening; early diagnosis; physicians; caregivers; payors; general public;
D O I
暂无
中图分类号
学科分类号
摘要
The IMPACT survey queried physicians, caregivers, payors and members of the general public from 5 European countries (France, Germany, Italy, Spain and the United Kingdom) regarding their opinions towards screening for Alzheimer’s disease (AD) as part of a 30-minute Web-based questionnaire conducted between April and May 2009. A larger proportion of caregivers (84%) and members of the general public (80%) than of physicians (56%) or payors (40%) viewed routine screening for AD as extremely or very important (P<0.001 for caregivers or general public vs physicians or payors). When asked if everyone should be routinely screened for AD at age 65, a smaller proportion of physicians (42%) and payors (44%) than members of the general public (81%) or caregivers (80%) agreed (P<0.001 for caregivers or general public vs physicians or payors). These opinions were generally consistent across the 5 countries for each respondent group. A notable exception was physician respondents from Italy, where most generalists and specialists actually favoured screening. Overall, generalists had a more positive attitude towards screening than specialists. The most frequently cited reason given by those who did not favour routine screening at age 65 was screening inaccuracy. This article discusses these results in relation to what screening is, when to screen and the barriers to screening. Despite the majority of IMPACT respondents being in favour of screening for AD, the evidence to support the introduction of population screening for cognitive impairment is not available; however, the importance of optimal identification of AD and other dementias in primary care should be a priority for community health professionals and payors. In order to do this effectively, further work is required to identify good assessment guidelines for use during opportunistic screening for cognitive impairment in primary care.
引用
收藏
页码:558 / 562
页数:4
相关论文
共 50 条
  • [41] To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers
    Ward, AJ
    Ishak, K
    Caro, J
    Torfs, K
    ANNALS OF NEUROLOGY, 2001, 50 (03) : S76 - S76
  • [42] Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Before and After Diagnosis
    Lin, Pei-Jung
    Zhong, Yue
    Fillit, Howard M.
    Chen, Er
    Neumann, Peter J.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2016, 64 (08) : 1549 - 1557
  • [43] The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey
    Caprioglio, Camilla
    Garibotto, Valentina
    Jessen, Frank
    Froelich, Lutz
    Allali, Gilles
    Assal, Frederic
    Frisoni, Giovanni B.
    Altomare, Daniele
    JOURNAL OF ALZHEIMERS DISEASE, 2022, 89 (02) : 535 - 551
  • [44] CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people withmild cognitive impairment (MCI) (Review)
    Ritchie, Craig
    Smailagica, Nadja
    Noel-Storr, Anna H.
    Ukoumunne, Obioha
    Ladds, Emma C.
    Martin, Steven
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (03):
  • [45] Assessment of CSF Aβ42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: A meta-analysis of 50 studies
    Tang, Wei
    Huang, Qiong
    Wang, Yan
    Wang, Zheng-Yu
    Yao, Yu-You
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2014, 345 (1-2) : 26 - 36
  • [46] Automated, online screening of mild cognitive impairment for Alzheimer's disease and related disorders
    Shankle, WR
    Hara, J
    Chen, J
    Chan, T
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S169 - S169
  • [47] Brief informant screening test for mild cognitive impairment and early Alzheimer's disease
    Li, Minglei
    Ng, Tze Pin
    Kua, Ee Heok
    Ko, Soo Meng
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2006, 21 (5-6) : 392 - 402
  • [48] Memory for Public Events in Mild Cognitive Impairment and Alzheimer's Disease: The Importance of Rehearsal
    Langlois, Roxane
    Joubert, Sven
    Benoit, Sophie
    Dostie, Valerie
    Rouleau, Isabelle
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 50 (04) : 1023 - 1033
  • [49] Differential Impairment of Cognitive and Affective Mentalizing Abilities in Neurodegenerative Dementias: Evidence from Behavioral Variant of Frontotemporal Dementia, Alzheimer's Disease, and Mild Cognitive Impairment
    Dodich, Alessandra
    Cerami, Chiara
    Crespi, Chiara
    Canessa, Nicola
    Lettieri, Giada
    Iannaccone, Sandro
    Marcone, Alessandra
    Cappa, Stefano F.
    Cacioppo, John T.
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 50 (04) : 1011 - 1022
  • [50] Covid-19 Susceptibility and Mortality Among Individuals With Mild Cognitive Impairment, Alzheimer's Disease and Related Dementias
    Pan, Alan
    Meeks, Jennifer
    Potter, Thomas
    Khan, Osman
    Seshadri, Sudha
    Masdeu, Joseph
    Vahidy, Farhaan S.
    STROKE, 2021, 52